BRISTOL MYERS SQUIBB
- Country
- ๐ซ๐ทFrance
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
- Conditions
- Interventions
- First Posted Date
- 2007-02-28
- Last Posted Date
- 2015-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 39
- Registration Number
- NCT00441337
- Locations
- ๐บ๐ธ
Washington University School of Medicine - Barnes Jewish Hospital, St. Louis, Missouri, United States
๐บ๐ธHenry Ford Health System, Detroit, Michigan, United States
๐บ๐ธCarolina BioOncology Institute, PLLC, Huntersville, North Carolina, United States
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
- First Posted Date
- 2007-02-23
- Last Posted Date
- 2014-03-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT00439270
- Locations
- ๐บ๐ธ
University of Chicago, Chicago, Illinois, United States
๐บ๐ธHematology-Oncology Associates Of Rockland, Nyack, New York, United States
๐บ๐ธDuke University, Durham, North Carolina, United States
A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 29
- Registration Number
- NCT00437437
- Locations
- ๐บ๐ธ
Dana-Farber Harvard Cancer Care, Boston, Massachusetts, United States
๐บ๐ธWayne State University, Detroit, Michigan, United States
๐บ๐ธDuke University Medical Center-Dept Of Medicine, Durham, North Carolina, United States
A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction
- First Posted Date
- 2007-02-21
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT00437424
- Locations
- ๐ช๐ธ
Local Institution, Sevilla, Spain
๐บ๐ธUniversity Of Alabama At Birmingham, Birmingham, Alabama, United States
๐บ๐ธUsc/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
- Conditions
- First Posted Date
- 2007-02-15
- Last Posted Date
- 2009-01-22
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT00435669
- Locations
- ๐บ๐ธ
Cleveland Clinic Foundation, Cleveland, Ohio, United States
Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis
- Conditions
- Interventions
- First Posted Date
- 2007-02-02
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 423
- Registration Number
- NCT00430677
- Locations
- ๐บ๐ธ
Wallace Rheumatic Study Center, Los Angeles, California, United States
๐บ๐ธNorthshore Lij Health System, Lake Success, New York, United States
๐บ๐ธOk Medical Research Foundation, Oklahoma City, Oklahoma, United States
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5407
- Registration Number
- NCT00423319
- Locations
- ๐บ๐ธ
Shrock Orthopedic Research, Ft. Lauderdale, Florida, United States
๐บ๐ธOrthoarkansas, P.A., Little Rock, Arkansas, United States
๐บ๐ธPab Clinical Research, Brandon, Florida, United States
A Study of Entecavir in Pediatric Patients With Chronic Hepatitis B Virus (HBV)-Infection
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2018-05-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 64
- Registration Number
- NCT00423891
- Locations
- ๐บ๐ธ
Connecticut Children'S Medical Center, Hartford, Connecticut, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
๐บ๐ธMount Sinai School Of Medicine, New York, New York, United States
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 37
- Registration Number
- NCT00420186
- Locations
- ๐บ๐ธ
Roswell Park Cancer Institute, Buffalo, New York, United States
๐บ๐ธPenn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
๐ฌ๐งLocal Institution, Manchester, Greater Manchester, United Kingdom
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT00420199
- Locations
- ๐ฌ๐ง
Local Institution, Leeds, North Yorkshire, United Kingdom